We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Pacific Biosciences of California (PACB) USD0.0001

Sell:$1.87 Buy:$1.88 Change: $0.07 (3.61%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.07 (3.61%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.07 (3.61%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Contact details

1305 O'brien Drive
United States
+1 (650) 5218000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$503.86 million
Shares in issue:
272.36 million
Life Sciences Tools & Services
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Christian Henry
    President, Chief Executive Officer, Director
  • Susan Kim
    Chief Financial Officer
  • Mark Van Oene
    Chief Operating Officer
  • Michele Farmer
    Chief Accounting Officer, Vice President
  • Brett Atkins
    General Counsel, Corporate Secretary
  • Jeff Eidel
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.